
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing phytonadione, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing phytonadione are listed in injection and tablet forms. It is also a component of FDA-approved kits.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Phytonadione is vitamin K1, a vitamin K replacement given by mouth or injection, that a pharmacy may compound when a prescriber orders it.
Phytonadione is vitamin K1, a fat-soluble vitamin. The liver needs vitamin K to make active forms of clotting factors II, VII, IX and X, as well as proteins C and S. Manufactured Vitamin K1 Injection is indicated for clotting disorders caused by vitamin K deficiency or by interference with vitamin K, including low prothrombin caused by coumarin or indanedione anticoagulants, by antibacterial therapy, or by conditions that limit vitamin K absorption or production such as obstructive jaundice and celiac disease. It is also indicated to prevent and treat vitamin K-deficiency bleeding in newborns. Phytonadione tablets are indicated for adults with these vitamin K-related clotting disorders. A prescriber might order phytonadione compounded in a strength or dosage form that is not manufactured, or in a vehicle without certain excipients. Compounded preparations are not FDA-approved and require a prescription.
The injection carries a boxed warning: fatal allergic reactions, including anaphylaxis, have occurred during and right after intravenous and intramuscular injection, even when diluted and on the first dose, so those routes are avoided unless the subcutaneous route is not feasible and the risk is justified. The injection contains benzyl alcohol, which can cause serious reactions and death in newborns; benzyl alcohol-free forms are preferred for infants and during breastfeeding. Injections can also cause skin reactions. Do not use phytonadione if allergic to it or any ingredient. It can cause temporary resistance to warfarin-type blood thinners; take warfarin only as directed, separate orlistat by 2 hours, and keep vitamin K-rich food intake steady. Vitamin K occurs naturally in breast milk, but a mother's supplements do not replace a newborn's vitamin K dose. Report unusual bruising or bleeding, and talk to your prescriber or pharmacist about side effects.
Phytonadione has the same activity as naturally occurring vitamin K, a cofactor for hepatic production of active factors II, VII, IX and X and proteins C and S. Oral phytonadione is adequately absorbed only when bile salts are present, and tablets generally act within 6 to 10 hours. Intravenous aqueous dispersion is generally detectable within 1 to 2 hours, with hemorrhage usually controlled within 3 to 6 hours and a normal INR often reached in 12 to 14 hours. Phytonadione concentrates initially in the liver, little accumulates in tissues, and almost no free unmetabolized drug appears in bile or urine. Labeled uses: hypoprothrombinemia from vitamin K deficiency or interference (Vitamin K1 Injection, phytonadione tablets) and prophylaxis and treatment of vitamin K-deficiency bleeding in neonates (Vitamin K1 Injection). StatPearls lists vitamin K antagonist-associated intracranial hemorrhage as an off-label use; it is not an FDA-approved indication. StatPearls notes intramuscular use is not recommended because of hematoma risk and that subcutaneous dosing did not reliably lower INR in one trial. Dosing is per prescriber. Monitor PT and INR. If anticoagulant resistance follows, higher anticoagulant doses or a different class such as heparin may be needed.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally